Climb Bio
CLYM
Climb Bio (CLYM) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.13
- EPS estimate
- −$0.19
- EPS surprise
- +29.73%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.19 | −$0.13 | +29.73% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.15 | −$0.31 | −106.67% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.15 | −$0.13 | +13.33% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | $0.00 | −$0.13 | +0.00% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | $0.00 | −$1.81 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.25 | −$0.84 | −236.00% | $0.00 | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.38 | −$0.29 | +23.68% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.43 | −$0.37 | +14.45% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$0.47 | −$0.56 | −19.99% | $0.00 | SEC |
| Q1 2022 | May 16, 2022 | −$0.56 | −$0.50 | +11.24% | $0.00 | SEC |
| Q4 2021 | Mar 7, 2022 | −$0.63 | −$0.40 | +36.51% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.89 | −$0.70 | +21.10% | $0.00 | SEC |
| Q2 2021 | Sep 13, 2021 | −$2.38 | −$3.11 | −30.95% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Climb Bio (CLYM) last report earnings?
Climb Bio last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did CLYM beat earnings estimates?
Yes. Climb Bio reported EPS of −$0.13 for Q2 2025 against a −$0.19 estimate — a 29.73% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.